18F-FDG PET/CT联合脑MRI与常规分期联合脑MRI在小细胞肺癌分期中的性能比较
该前瞻性研究纳入59例病理确诊的小细胞肺癌患者,比较整合18F-FDG PET/CT与常规分期(均联合增强脑MRI)在TNM因素识别、TNM及VALSG分期和I期患者筛选中的能力。PET/CT对N因素和TNM分期的诊断准确率显著高于常规分期联合增强脑MRI(N:89.8% vs 67.8%,P=0.0002;TNM分期:88.1% vs 72.9%,P=0.004)。结论认为整合FDG PET/CT联合增强脑MRI在T、N、M评估及TNM和VALSG分期方面可能等于或优于常规分期联合增强脑MRI。
要点
- PET/CT对N因素识别准确率89.8%(53/59),高于常规分期联合脑MRI的67.8%(40/59),P=0.0002。
- PET/CT对TNM分期准确率88.1%(52/59),高于常规分期联合脑MRI的72.9%(43/59),P=0.004。
- PET/CT各因素及分期观察者间一致性几乎完美(0.83≤κ≤0.93,P<0.001)。
核心结论
- 整合FDG PET/CT联合增强脑MRI在T、N、M评估及TNM和VALSG分期方面可能等于或优于常规分期联合增强脑MRI。
研究设计与样本
- 前瞻性研究,纳入59例病理确诊的小细胞肺癌患者(平均年龄69.6±7.8岁,范围40-84岁),行整合18F-FDG PET/CT和常规分期(均联合增强脑MRI),由两组不同阅片者评估TNM和VALSG分期,采用Kappa统计量和卡方检验评估观察者间一致性,McNemar检验比较诊断准确率。
诊断标准与关键数值
- PET/CT对N因素诊断准确率89.8%(53/59),常规分期联合增强脑MRI为67.8%(40/59),P=0.0002。
- PET/CT对TNM分期诊断准确率88.1%(52/59),常规分期联合增强脑MRI为72.9%(43/59),P=0.004。
- PET/CT各因素及分期观察者间一致性几乎完美(0.83≤κ≤0.93,P<0.001)。
- 常规分期联合增强脑MRI观察者间一致性为中等至几乎完美(0.63≤κ≤0.96,P<0.001)。
临床应用与阅片要点
- 作者认为整合FDG PET/CT联合增强脑MRI在T、N、M评估及TNM和VALSG分期方面可能等于或优于常规分期联合增强脑MRI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The purpose of this study was to prospectively compare the capabilities of integrated FDG PET/CT and conventional staging for identification of TNM factors, evaluation of the TNM and Veterans Administration Lung Study Group (VALSG) stages, and selection of patients with stage I small cell lung carcinoma (SCLC).
SUBJECTS AND METHODS: Fifty-nine patients (mean age, 69.6 ± 7.8 [SD] years; range, 40-84 years) with pathologically diagnosed SCLC underwent integrated 18F-FDG PET/CT and conventional staging with enhanced brain MRI. TNM and VALSG stages were evaluated by two different reader groups. Kappa statistics and chi-square test result were determined for evaluations of interobserver agreement of all factors and for each clinical stage for both methods. Diagnostic accuracy of identification of each factor and clinical stage was statistically compared by McNemar test.
RESULTS: Interobserver agreements for all factors and each clinical stage were assessed as almost perfect for PET/CT (0.83 ≤ κ ≤ 0.93; p < 0.001) and substantial and almost perfect (0.63 ≤ κ ≤ 0.96; p < 0.001) for conventional staging plus enhanced brain MRI. The diagnostic accuracy of PET/CT for N factor and TNM stage (N, 89.8% [53/59]; TNM stage, 88.1% [52/59]) was significantly higher than that of conventional staging plus enhanced brain MRI (N, 67.8% [40/59], p = 0.0002; TNM stage, 72.9% [43/59], p = 0.004).
CONCLUSION: Integrated FDG PET/CT with contrast-enhanced brain MRI is potentially equal to or more effective than conventional staging plus enhanced brain MRI for T, N, and M assessment and TNM and VALSG staging of SCLC.
引用
- Kishida Y, Seki S, Yoshikawa T, et al. Performance Comparison Between 18F-FDG PET/CT Plus Brain MRI and Conventional Staging Plus Brain MRI in Staging of Small Cell Lung Carcinoma. AJR Am J Roentgenol. 2018. PMID: 29667886. doi:10.2214/AJR.17.18935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。